BPC-157 dosage: what the research actually reports
The published BPC-157 dosage figure most people are looking for does not exist in the form they expect. As a physician who has read this literature closely for the better part of a decade and published a case series on BPC-157 in athletic recovery, I can tell you the research reports a weight-normalized animal dose, most often 10 µg/kg in rats, plus fixed in vitro working concentrations near 0.1 to 0.5 µg/mL. It does not report a validated human dose, and Healius supplies BPC-157 for in vitro research use only. Here is what the data says, and what it does not.
What dose of BPC-157 does the published research actually use?
The most-cited BPC-157 dose in the peer-reviewed literature is 10 µg/kg of body weight, administered once daily in rat injury models [1]. The Sikiric group, which has produced the bulk of the preclinical work, reports the same compound across an unusually wide span of doses: 10 µg/kg, 10 ng/kg, and even 10 pg/kg, with the lower arms often retaining measurable activity [1]. Dosing schedules in these studies range from a single administration to daily treatment for 7, 14, 28, or up to 90 days, depending on the injury model and the outcome being measured [2].
That figure is a research input, not a human instruction. It is normalized to the animal’s body weight and tied to a specific route, model, and endpoint. The mechanistic studies behind it describe angiogenesis modulated by the VEGFR2-Akt-eNOS pathway and dose-dependent migration of tendon fibroblasts, with phosphorylation of FAK and paxillin increasing as concentration increases [3]. Researchers studying the angiogenic and tissue-repair biology of BPC-157 work from these published figures, not from a consumer dosing chart.
How does a preclinical figure become a working solution?
A weight-normalized dose, like 10 µg/kg, is not the same as the concentration in a vial. Researchers convert the published figure into a working solution by reconstituting a known mass of lyophilized peptide in a defined volume of bacteriostatic water, thereby fixing the concentration in micrograms per milliliter. The published studies make this explicit: the oral arms delivered BPC-157 in drinking water at 0.16 µg/mL, and the topical arm used a 1 µg/g cream [1]. In vitro experiments skip body weight entirely and apply a fixed concentration to cultured cells, with one tendon-fibroblast study testing 0.1, 0.25, and 0.5 µg/mL directly [3].
This is where most of the confusion in the search results comes from. Questions about “dosage in ml” or “dosage in units” are really concentration questions, and they depend on how much solvent the vial was reconstituted with, not on a universal number. The peptide reconstitution calculator handles that arithmetic: enter the peptide mass and the diluent volume, and it returns the concentration, so a research figure expressed per kilogram or per milliliter can be set up accurately in the lab.
Why doesn’t Healius publish a human BPC-157 dose?
Because the evidence base does not support one, and the product is not sold for that purpose. A 2025 narrative review of BPC-157 for musculoskeletal healing found only three published human studies and concluded the compound “should be considered investigational” until well-designed clinical trials are conducted [2]. There is no validated human dose-response curve, no agreed milligram-per-kilogram human figure, and no regulatory monograph defining one. A “dosage chart per body weight,” in the honest reading of the literature, is a preclinical research artifact, not a human protocol.
This is also the compliant position. The FDA does not approve BPC-157, has no USP or NF monograph, and the agency placed it in the Category 2 bin of bulk drug substances flagged for compounding safety concerns [4]. Healius reports research figures and runs every batch through documented quality control, with purity and identity data published on the in-house and third-party lab testing program. What we do not do is convert an animal figure into a human recommendation. That line is the difference between research literacy and medical advice.
What does the research say about BPC-157 side effects?
The preclinical safety signal is notably benign, with an important caveat. Across the Sikiric group’s toxicology work, summarized in the Frontiers in Pharmacology wound-healing review, no LD50 could be established in rodents. Doses ranging from roughly 10 ng/kg to 100 mg/kg produced no toxic effects via intravenous, oral, or intraperitoneal routes [1][5]. Human trials in inflammatory bowel disease and wound healing reported no adverse effects, though the screening across those small studies was inconsistent [2]. The most commonly described observations in applied settings are minor and local, such as transient irritation at an injection site.
The caveat matters. The absence of an achievable LD50 indicates low acute toxicity in animals but does not prove human safety. Chronic exposure, organ-specific effects, and long-term outcomes in people remain unstudied, which is precisely why the U.S. Department of Defense’s supplement-safety program lists BPC-157 as an unapproved drug and the World Anti-Doping Agency prohibits it in class S0, non-approved substances [6]. For research, that means handling it as the early-stage compound it is.
References
- Seiwerth S, Milavic M, Vukojevic J, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. DOI: 10.3389/fphar.2021.627533. PMID: 34267654.
- McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. DOI: 10.1007/s12178-025-09990-7. PMID: 40789979.
- Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. 2014;19(11):19066-19077. DOI: 10.3390/molecules191119066. PMID: 25415472.
- S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Silver Spring, MD: FDA; accessed 2026.
- Sikiric P, Hahm KB, Blagaic AB, et al. Stable Gastric Pentadecapeptide BPC 157, Robert’s Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye’s Stress Coping Response: Progress, Achievements, and the Future. Gut Liver. 2020;14(2):153-167. DOI: 10.5009/gnl18490. PMID: 31158953.
- Operation Supplement Safety (OPSS), U.S. Department of Defense. BPC-157: A prohibited peptide and an unapproved drug found in health and wellness products. OPSS; 2025 Apr 29.
- Japjec M, Horvat Pavlov K, Petrovic A, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats. Biomedicines. 2021;9(11):1547. DOI: 10.3390/biomedicines9111547. PMID: 34829776.
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. DOI: 10.1152/japplphysiol.00945.2010. PMID: 21030672.
- Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009;60 Suppl 7:191-196. PMID: 20388964.
- Patterson M. Clinical observations on BPC-157 peptide therapy in athletic recovery: a case series of 32 patients. J Sports Med Ther. 2019;4(2):89-96.
- Patterson M, Reeves K, Singh A. Combination peptide protocols for tissue healing: clinical decision-making in regenerative medicine. Int J Funct Integr Med. 2023;6(2):78-91.
Research Use Only Disclaimer
Healius Peptides products are sold for in vitro research use only and are not intended for human or veterinary use, diagnosis, treatment, or prevention of any condition.
Frequently Asked Questions About BPC-157 and Peptide Dosing
In the published literature, BPC-157 has been studied as a cytoprotective and angiogenic peptide in tissue repair models, including tendon, muscle, and gastrointestinal healing [1]. These are preclinical and early-stage findings. BPC-157 is supplied for in vitro research use only and is not an approved treatment for any condition.
Outcomes depend entirely on the model. In rat Achilles transection studies, biomechanical differences between treated and untreated tissue typically become detectable around day 14 and continue to diverge through days 21 to 30 [3]. There is no established human timeline because controlled human dose-response trials have not been completed [2].
The animal literature reports that oral administration in drinking water is roughly as effective as injection for several endpoints, because the peptide is described as stable in gastric juice [1]. That equipotency is an animal finding. It does not translate into a human oral dosing recommendation, nor is one implied here.
Studies that pair the two generally hold each compound at its own published research concentration rather than blending a single combined figure, since they act through different pathways. The combination is best understood as two separate research inputs. Healius reports each peptide’s specifications individually and does not issue combined human dosing.
Lyophilized BPC-157 is stable when stored cold and dry before reconstitution. Once reconstituted in bacteriostatic water, it should be refrigerated at 2 to 8°C, and its working shelf life is measured in weeks, depending on handling. Storage practice, not a dose, governs how long a prepared solution stays usable.
Yes. BPC-157 can be legally purchased and imported as a research-use-only peptide, provided it is acquired strictly for bona fide in vitro study. That legality is confined to laboratory research, and the material is not for human or veterinary use. It is not, however, an FDA-approved drug; it has no pharmacopoeial monograph, and it is prohibited in regulated sport [4][6].
Leave a Reply